Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Blagden SP. et al, (2022), British journal of cancer
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones R. et al, (2022), Clin cancer res
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ. et al, (2022), J immunother cancer, 10
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR. et al, (2022), Lancet oncol
PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials
Nicum S. and Blagden SP., (2022), Clinical cancer research
Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.
Pantziarka P. and Blagden S., (2022), Cancers (basel), 14
Targeting MAPK in recurrent, low-grade serous ovarian cancer.
Blagden SP., (2022), Lancet (london, england), 399, 499 - 501
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi F. et al, (2021), Cochrane database of systematic reviews, 2021
The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial.
Schwenzer H. et al, (2021), Clin cancer res